Lupin received USFDA approval for Ethacrynic Acid Tablets USP, 25 mg

Lupin announced that it has received approval for its Ethacrynic Acid Tablets USP, 25 mg, from the United States Food and Drug Administration (USFDA).

Lupin's Ethacrynic Acid Tablets USP, 25 mg, is the generic version of Edecrin Tablets, 25 mg, of Bausch Health Americas, Inc.

Ethacrynic Acid Tablets USP (RLD: Edecrin Tablets) had annual sales of approximately USD 24 million in the US (IQVIA MAT June 2019).

Powered by Capital Market - Live News